Dataset Information

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

ABSTRACT: The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ?5 EpCAMhigh CTC and 28% had ?5 EpCAMlow CTC. For breast cancer patients, 32% had ?5 EpCAMhigh CTC and 36% had ?5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ?5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ?5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.

SUBMITTER: de Wit S

PROVIDER: S-EPMC6235023 | biostudies-other | 2018 Nov

REPOSITORIES: biostudies-other

ACCESS DATA

Publications

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

de Wit Sanne S Manicone Mariangela M Rossi Elisabetta E Lampignano Rita R Yang Liwen L Zill Beate B Rengel-Puertas Alvera A Ouhlen Marianne M Crespo Mateus M Berghuis Anne Margreet Sofie AMS Andree Kiki Carlijn KC Vidotto Riccardo R Trapp Elisabeth Katharina EK Tzschaschel Marie M Colomba Emeline E Fowler Gemma G Flohr Penelope P Rescigno Pasquale P Fontes Mariane Sousa MS Zamarchi Rita R Fehm Tanja T Neubauer Hans H Rack Brigitte B Alunni-Fabbroni Marianna M Farace Françoise F De Bono Johann J IJzerman Maarten Joost MJ Terstappen Leonardus Wendelinus Mathias Marie LWMM

Oncotarget 20181102 86

The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followe ...[more]

PMID: 30479699

Similar Datasets

Project description:Traditional factors currently used for prognostic stratification do not always adequately predict treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in breast cancer patients with limited metastatic dissemination.A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood, pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at baseline and at the time of treatment failure, using Fisher's exact test. Time to visceral progression and time to the development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between groups according to pretreatment CTC count by logrank test.In the overall population, a pretreatment level ?5 CTCs/7.5 ml was associated with an increased baseline number of metastatic sites compared with <5 CTCs/7.5 ml (P?=?0.0077). At the time of treatment failure, patients with ?5 CTCs/7.5 ml more frequently developed new metastatic lesions and sites compared with those with <5 CTCs/7.5 ml (development of new lesions: P?=?0.0002; development of new sites: P?=?0.0031). Among patients with disease originally confined to nonvisceral sites, ?5 CTCs/7.5 ml was associated with remarkably shorter time to visceral metastases (P?=?0.0021) and overall survival (P?=?0.0006) compared with <5 CTCs/7.5 ml. In patients with single-site metastatic disease, ?5 CTCs/7.5 ml was associated with a significant reduction of the time to development of new metastatic sites (P?=?0.0051) and new lesions (P?=?0.0002) and with worse overall survival (P?=?0.0101).Our results suggest that baseline CTC counts can be used as an early predictor of metastatic potential in breast cancer patients with limited metastatic dissemination.

Dataset Information

EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients.

Publications

EpCAM<sup>high</sup> and EpCAM<sup>low</sup> circulating tumor cells in metastatic prostate and breast cancer patients.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets